• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021

    12/9/21 10:27:20 AM ET
    $ABBV
    $ALL
    $ALSN
    $AMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Property-Casualty Insurers
    Finance
    Get the next $ABBV alert in real time by email

    Upgrades

    According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ:NVEI) was changed from Market Perform to Outperform.

    BMO Capital upgraded the previous rating for Nuvei Corp (NASDAQ:NVEI) from Market Perform to Outperform.

    For Cadence Bank (NYSE:CADE), Janney Montgomery Scott upgraded the previous rating of Neutral to Buy. Cadence Bank earned $0.67 in the third quarter, compared to $0.40 in the year-ago quarter. At the moment, the stock has a 52-week-high of $32.12 and a 52-week-low of $14.47. Cadence Bank closed at $29.39 at the end of the last trading period.

    According to Raymond James, the prior rating for Boyd Gaming Corp (NYSE:BYD) was changed from Outperform to Strong Buy. For the third quarter, Boyd Gaming had an EPS of $1.30, compared to year-ago quarter EPS of $0.38. The current stock performance of Boyd Gaming shows a 52-week-high of $71.00 and a 52-week-low of $40.44. Moreover, at the end of the last trading period, the closing price was at $64.48.

    Wells Fargo upgraded the previous rating for LGI Homes Inc (NASDAQ:LGIH) from Underweight to Equal-Weight. In the third quarter, LGI Homes showed an EPS of $4.05, compared to $2.45 from the year-ago quarter. The current stock performance of LGI Homes shows a 52-week-high of $188.00 and a 52-week-low of $95.54. Moreover, at the end of the last trading period, the closing price was at $155.99.

    For Twilio Inc (NYSE:TWLO), Barclays upgraded the previous rating of Equal-Weight to Overweight. In the third quarter, Twilio showed an EPS of $0.01, compared to $0.04 from the year-ago quarter. At the moment, the stock has a 52-week-high of $457.30 and a 52-week-low of $235.00. Twilio closed at $274.81 at the end of the last trading period.

    Stifel upgraded the previous rating for JFrog Ltd (NASDAQ:FROG) from Hold to Buy. JFrog earned $0.01 in the third quarter, compared to $0.05 in the year-ago quarter. At the moment, the stock has a 52-week-high of $72.28 and a 52-week-low of $27.65. JFrog closed at $32.37 at the end of the last trading period.

    Oppenheimer upgraded the previous rating for Sarepta Therapeutics Inc (NASDAQ:SRPT) from Perform to Outperform. For the third quarter, Sarepta Therapeutics had an EPS of $0.19, compared to year-ago quarter EPS of $1.42. The stock has a 52-week-high of $181.83 and a 52-week-low of $65.30. At the end of the last trading period, Sarepta Therapeutics closed at $86.02.

    For Engagesmart Inc (NYSE:ESMT), Citigroup upgraded the previous rating of Neutral to Buy. In the third quarter, Engagesmart showed an EPS of $0.06, compared to $0.00 from the year-ago quarter.

    Credit Suisse upgraded the previous rating for CVR Energy Inc (NYSE:CVI) from Underperform to Neutral. CVR Energy earned $0.24 in the third quarter, compared to $0.57 in the year-ago quarter. At the moment, the stock has a 52-week-high of $27.02 and a 52-week-low of $11.22. CVR Energy closed at $16.50 at the end of the last trading period.

    For UiPath Inc (NYSE:PATH), Berenberg upgraded the previous rating of Hold to Buy. UiPath earned $0.00 in the third quarter, compared to $0.41 in the year-ago quarter. The current stock performance of UiPath shows a 52-week-high of $90.00 and a 52-week-low of $42.02. Moreover, at the end of the last trading period, the closing price was at $47.71.

    Wolfe Research upgraded the previous rating for Linde PLC (NYSE:LIN) from Peer Perform to Outperform. In the third quarter, Linde showed an EPS of $2.73, compared to $2.15 from the year-ago quarter. At the moment, the stock has a 52-week-high of $340.16 and a 52-week-low of $240.80. Linde closed at $333.19 at the end of the last trading period.

    Needham upgraded the previous rating for Inogen Inc (NASDAQ:INGN) from Hold to Buy. In the third quarter, Inogen showed an EPS of $0.53, compared to $0.08 from the year-ago quarter. The stock has a 52-week-high of $82.35 and a 52-week-low of $29.28. At the end of the last trading period, Inogen closed at $33.08.

    For Instructure Holdings Inc (NYSE:INST), Morgan Stanley upgraded the previous rating of Equal-Weight to Overweight. For the third quarter, Instructure Holdings had an EPS of $0.24, compared to year-ago quarter EPS of $0.13.

    Morgan Stanley upgraded the previous rating for United Rentals Inc (NYSE:URI) from Underweight to Equal-Weight. In the third quarter, United Rentals showed an EPS of $6.58, compared to $5.40 from the year-ago quarter. The current stock performance of United Rentals shows a 52-week-high of $414.99 and a 52-week-low of $217.39. Moreover, at the end of the last trading period, the closing price was at $356.96.

    Barclays upgraded the previous rating for CRH PLC (NYSE:CRH) from Underweight to Equal-Weight. The current stock performance of CRH shows a 52-week-high of $53.99 and a 52-week-low of $39.10. Moreover, at the end of the last trading period, the closing price was at $50.94.

    Atlantic Equities upgraded the previous rating for Yum Brands Inc (NYSE:YUM) from Neutral to Overweight. For the third quarter, Yum Brands had an EPS of $1.22, compared to year-ago quarter EPS of $1.01. At the moment, the stock has a 52-week-high of $135.77 and a 52-week-low of $101.18. Yum Brands closed at $131.74 at the end of the last trading period.

    According to JP Morgan, the prior rating for Brookfield Renewable Partners LP (NYSE:BEP) was changed from Neutral to Overweight. Brookfield Renewable earned $0.21 in the third quarter, compared to $0.44 in the year-ago quarter. The stock has a 52-week-high of $88.41 and a 52-week-low of $33.56. At the end of the last trading period, Brookfield Renewable closed at $34.38.

    According to JP Morgan, the prior rating for Brookfield Renewable Corp (NYSE:BEPC) was changed from Neutral to Overweight. At the moment, the stock has a 52-week-high of $107.83 and a 52-week-low of $34.13. Brookfield Renewable closed at $34.90 at the end of the last trading period.

    For Occidental Petroleum Corp (NYSE:OXY), JP Morgan upgraded the previous rating of Underweight to Neutral. Occidental Petroleum earned $0.87 in the third quarter, compared to $0.84 in the year-ago quarter. The current stock performance of Occidental Petroleum shows a 52-week-high of $35.75 and a 52-week-low of $16.88. Moreover, at the end of the last trading period, the closing price was at $30.77.

    Morgan Stanley upgraded the previous rating for Rio Tinto PLC (NYSE:RIO) from Equal-Weight to Overweight. The current stock performance of Rio Tinto shows a 52-week-high of $95.97 and a 52-week-low of $59.58. Moreover, at the end of the last trading period, the closing price was at $63.88.

    JP Morgan upgraded the previous rating for Phillips 66 (NYSE:PSX) from Neutral to Overweight. For the third quarter, Phillips 66 had an EPS of $3.18, compared to year-ago quarter EPS of $0.01. The stock has a 52-week-high of $94.34 and a 52-week-low of $63.19. At the end of the last trading period, Phillips 66 closed at $71.85.

    See all analyst ratings upgrades.

    Downgrades

    According to Goldman Sachs, the prior rating for Reata Pharmaceuticals Inc (NASDAQ:RETA) was changed from Buy to Neutral. Reata Pharmaceuticals earned $1.27 in the third quarter, compared to $1.31 in the year-ago quarter. At the moment, the stock has a 52-week-high of $153.41 and a 52-week-low of $32.00. Reata Pharmaceuticals closed at $54.42 at the end of the last trading period.

    According to RBC Capital, the prior rating for Diageo PLC (NYSE:DEO) was changed from Sector Perform to Underperform. At the moment, the stock has a 52-week-high of $213.12 and a 52-week-low of $153.67. Diageo closed at $211.93 at the end of the last trading period.

    According to Jefferies, the prior rating for Southwest Airlines Co (NYSE:LUV) was changed from Buy to Hold. In the third quarter, Southwest Airlines showed an EPS of $0.23, compared to $1.99 from the year-ago quarter. The stock has a 52-week-high of $64.75 and a 52-week-low of $42.39. At the end of the last trading period, Southwest Airlines closed at $45.27.

    For Snap One Holdings Corp (NASDAQ:SNPO), Morgan Stanley downgraded the previous rating of Overweight to Equal-Weight. In the third quarter, Snap One Holdings showed an EPS of $0.24, compared to $0.02 from the year-ago quarter.

    Morgan Stanley downgraded the previous rating for Liberty SiriusXM Group (NASDAQ:LSXMA) from Overweight to Equal-Weight. The current stock performance of Liberty SiriusXM Gr shows a 52-week-high of $56.26 and a 52-week-low of $39.40. Moreover, at the end of the last trading period, the closing price was at $48.46.

    SVB Leerink downgraded the previous rating for Reata Pharmaceuticals Inc (NASDAQ:RETA) from Outperform to Market Perform. For the third quarter, Reata Pharmaceuticals had an EPS of $1.27, compared to year-ago quarter EPS of $1.31. The current stock performance of Reata Pharmaceuticals shows a 52-week-high of $153.41 and a 52-week-low of $32.00. Moreover, at the end of the last trading period, the closing price was at $54.42.

    For Air Products & Chemicals Inc (NYSE:APD), Wolfe Research downgraded the previous rating of Outperform to Peer Perform. In the fourth quarter, Air Products & Chemicals showed an EPS of $2.51, compared to $2.19 from the year-ago quarter. The current stock performance of Air Products & Chemicals shows a 52-week-high of $316.39 and a 52-week-low of $245.75. Moreover, at the end of the last trading period, the closing price was at $295.67.

    According to Morgan Stanley, the prior rating for Charter Communications Inc (NASDAQ:CHTR) was changed from Overweight to Equal-Weight. For the third quarter, Charter Communications had an EPS of $6.50, compared to year-ago quarter EPS of $3.90. At the moment, the stock has a 52-week-high of $825.62 and a 52-week-low of $585.45. Charter Communications closed at $642.07 at the end of the last trading period.

    According to Morgan Stanley, the prior rating for Allison Transmission Holdings Inc (NYSE:ALSN) was changed from Equal-Weight to Underweight. For the third quarter, Allison Transmission had an EPS of $0.89, compared to year-ago quarter EPS of $0.68. The stock has a 52-week-high of $46.40 and a 52-week-low of $32.55. At the end of the last trading period, Allison Transmission closed at $36.12.

    For Reata Pharmaceuticals Inc (NASDAQ:RETA), Baird downgraded the previous rating of Outperform to Neutral. For the third quarter, Reata Pharmaceuticals had an EPS of $1.27, compared to year-ago quarter EPS of $1.31. The stock has a 52-week-high of $153.41 and a 52-week-low of $32.00. At the end of the last trading period, Reata Pharmaceuticals closed at $54.42.

    For Zimmer Biomet Holdings Inc (NYSE:ZBH), Needham downgraded the previous rating of Strong Buy to Buy. Zimmer Biomet Holdings earned $1.81 in the third quarter, compared to $1.81 in the year-ago quarter. At the moment, the stock has a 52-week-high of $180.36 and a 52-week-low of $119.55. Zimmer Biomet Holdings closed at $128.96 at the end of the last trading period.

    JP Morgan downgraded the previous rating for Canadian Natural Resources Ltd (NYSE:CNQ) from Overweight to Neutral. Canadian Natural Res earned $1.41 in the third quarter, compared to $0.08 in the year-ago quarter. The current stock performance of Canadian Natural Res shows a 52-week-high of $44.33 and a 52-week-low of $22.40. Moreover, at the end of the last trading period, the closing price was at $43.07.

    According to JP Morgan, the prior rating for Altice USA Inc (NYSE:ATUS) was changed from Overweight to Neutral. In the third quarter, Altice USA showed an EPS of $0.58, compared to $0.32 from the year-ago quarter. The current stock performance of Altice USA shows a 52-week-high of $38.30 and a 52-week-low of $15.47. Moreover, at the end of the last trading period, the closing price was at $15.86.

    According to JP Morgan, the prior rating for Enviva Partners LP (NYSE:EVA) was changed from Overweight to Neutral. Enviva Partners earned $0.63 in the third quarter, compared to $0.28 in the year-ago quarter. The current stock performance of Enviva Partners shows a 52-week-high of $73.33 and a 52-week-low of $44.01. Moreover, at the end of the last trading period, the closing price was at $72.95.

    JP Morgan downgraded the previous rating for SunPower Corp (NASDAQ:SPWR) from Neutral to Underweight. SunPower earned $0.06 in the third quarter, compared to $0.04 in the year-ago quarter. At the moment, the stock has a 52-week-high of $57.52 and a 52-week-low of $19.75. SunPower closed at $24.94 at the end of the last trading period.

    According to RBC Capital, the prior rating for Cincinnati Financial Corp (NASDAQ:CINF) was changed from Outperform to Sector Perform. In the third quarter, Cincinnati Financial showed an EPS of $1.28, compared to $0.39 from the year-ago quarter. The current stock performance of Cincinnati Financial shows a 52-week-high of $127.25 and a 52-week-low of $78.56. Moreover, at the end of the last trading period, the closing price was at $117.21.

    According to RBC Capital, the prior rating for Marsh & McLennan Companies Inc (NYSE:MMC) was changed from Outperform to Sector Perform. In the third quarter, Marsh & McLennan showed an EPS of $1.08, compared to $0.82 from the year-ago quarter. At the moment, the stock has a 52-week-high of $174.90 and a 52-week-low of $106.95. Marsh & McLennan closed at $172.91 at the end of the last trading period.

    According to JP Morgan, the prior rating for CVR Energy Inc (NYSE:CVI) was changed from Neutral to Underweight. In the third quarter, CVR Energy showed an EPS of $0.24, compared to $0.57 from the year-ago quarter. The current stock performance of CVR Energy shows a 52-week-high of $27.02 and a 52-week-low of $11.22. Moreover, at the end of the last trading period, the closing price was at $16.50.

    According to Chardan Capital, the prior rating for Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) was changed from Buy to Neutral. Dicerna Pharmaceuticals earned $0.22 in the third quarter, compared to $0.29 in the year-ago quarter. The current stock performance of Dicerna Pharmaceuticals shows a 52-week-high of $40.14 and a 52-week-low of $19.06. Moreover, at the end of the last trading period, the closing price was at $38.00.

    According to Wells Fargo, the prior rating for Allstate Corp (NYSE:ALL) was changed from Equal-Weight to Underweight. Allstate earned $0.73 in the third quarter, compared to $2.94 in the year-ago quarter. At the moment, the stock has a 52-week-high of $140.00 and a 52-week-low of $102.44. Allstate closed at $109.02 at the end of the last trading period.

    See all analyst ratings downgrades.

    Initiations

    With a Buy rating, EF Hutton initiated coverage on Trxade Health Inc (NASDAQ:MEDS). The price target seems to have been set at $4.50 for Trxade Health. In the third quarter, Trxade Health showed an EPS of $0.16, compared to $0.02 from the year-ago quarter. At the moment, the stock has a 52-week-high of $10.82 and a 52-week-low of $2.61. Trxade Health closed at $3.06 at the end of the last trading period.

    With a Buy rating, Alliance Global Partners initiated coverage on XORTX Therapeutics Inc (NASDAQ:XRTX). The price target seems to have been set at $11.00 for XORTX Therapeutics. XORTX Therapeutics earned $0.03 in the fourth quarter, compared to $0.24 in the year-ago quarter.

    Truist Securities initiated coverage on WR Berkley Corp (NYSE:WRB) with a Buy rating. The price target for WR Berkley is set to $105.00. For the third quarter, WR Berkley had an EPS of $1.32, compared to year-ago quarter EPS of $0.65. The current stock performance of WR Berkley shows a 52-week-high of $84.93 and a 52-week-low of $61.49. Moreover, at the end of the last trading period, the closing price was at $79.90.

    Wells Fargo initiated coverage on AbbVie Inc (NYSE:ABBV) with an Overweight rating. The price target for AbbVie is set to $165.00. For the third quarter, AbbVie had an EPS of $3.33, compared to year-ago quarter EPS of $2.83. The current stock performance of AbbVie shows a 52-week-high of $122.45 and a 52-week-low of $101.55. Moreover, at the end of the last trading period, the closing price was at $121.87.

    Wells Fargo initiated coverage on Regeneron Pharmaceuticals Inc (NASDAQ:REGN) with an Overweight rating. The price target for Regeneron Pharmaceuticals is set to $750.00. Regeneron Pharmaceuticals earned $15.37 in the third quarter, compared to $8.36 in the year-ago quarter. The current stock performance of Regeneron Pharmaceuticals shows a 52-week-high of $686.62 and a 52-week-low of $441.00. Moreover, at the end of the last trading period, the closing price was at $654.04.

    Wells Fargo initiated coverage on Vertex Pharmaceuticals Inc (NASDAQ:VRTX) with an Overweight rating. The price target for Vertex Pharmaceuticals is set to $270.00. In the third quarter, Vertex Pharmaceuticals showed an EPS of $3.56, compared to $2.64 from the year-ago quarter. The stock has a 52-week-high of $242.99 and a 52-week-low of $176.36. At the end of the last trading period, Vertex Pharmaceuticals closed at $206.61.

    With an Overweight rating, Wells Fargo initiated coverage on Merck & Co Inc (NYSE:MRK). The price target seems to have been set at $90.00 for Merck & Co. For the third quarter, Merck & Co had an EPS of $1.75, compared to year-ago quarter EPS of $1.74. At the moment, the stock has a 52-week-high of $91.40 and a 52-week-low of $15.32. Merck & Co closed at $73.21 at the end of the last trading period.

    Wells Fargo initiated coverage on Biogen Inc (NASDAQ:BIIB) with a Equal-Weight rating. The price target for Biogen is set to $250.00. For the third quarter, Biogen had an EPS of $4.77, compared to year-ago quarter EPS of $8.84. The current stock performance of Biogen shows a 52-week-high of $468.55 and a 52-week-low of $221.72. Moreover, at the end of the last trading period, the closing price was at $234.72.

    Wells Fargo initiated coverage on Pfizer Inc (NYSE:PFE) with an Overweight rating. The price target for Pfizer is set to $60.00. Pfizer earned $1.34 in the third quarter, compared to $0.72 in the year-ago quarter. At the moment, the stock has a 52-week-high of $55.70 and a 52-week-low of $33.36. Pfizer closed at $51.40 at the end of the last trading period.

    With a Equal-Weight rating, Wells Fargo initiated coverage on Bristol-Myers Squibb Co (NYSE:BMY). The price target seems to have been set at $58.00 for Bristol-Myers Squibb. In the third quarter, Bristol-Myers Squibb showed an EPS of $2.00, compared to $1.63 from the year-ago quarter. The current stock performance of Bristol-Myers Squibb shows a 52-week-high of $69.75 and a 52-week-low of $53.22. Moreover, at the end of the last trading period, the closing price was at $57.60.

    Wells Fargo initiated coverage on Amgen Inc (NASDAQ:AMGN) with a Equal-Weight rating. The price target for Amgen is set to $210.00. In the third quarter, Amgen showed an EPS of $4.67, compared to $4.37 from the year-ago quarter. The current stock performance of Amgen shows a 52-week-high of $276.69 and a 52-week-low of $198.64. Moreover, at the end of the last trading period, the closing price was at $213.53.

    Wells Fargo initiated coverage on Gilead Sciences Inc (NASDAQ:GILD) with a Equal-Weight rating. The price target for Gilead Sciences is set to $72.00. In the third quarter, Gilead Sciences showed an EPS of $2.65, compared to $2.11 from the year-ago quarter. The current stock performance of Gilead Sciences shows a 52-week-high of $73.34 and a 52-week-low of $56.56. Moreover, at the end of the last trading period, the closing price was at $69.71.

    With a Equal-Weight rating, Wells Fargo initiated coverage on Eli Lilly and Co (NYSE:LLY). The price target seems to have been set at $270.00 for Eli Lilly. In the third quarter, Eli Lilly showed an EPS of $1.94, compared to $1.54 from the year-ago quarter. At the moment, the stock has a 52-week-high of $275.87 and a 52-week-low of $146.91. Eli Lilly closed at $244.32 at the end of the last trading period.

    Maxim Group initiated coverage on Recruiter.Com Group Inc (NASDAQ:RCRT) with a Buy rating. The price target for Recruiter.Com Group is set to $9.00. The current stock performance of Recruiter.Com Group shows a 52-week-high of $5.86 and a 52-week-low of $1.55. Moreover, at the end of the last trading period, the closing price was at $3.76.

    Macquarie initiated coverage on Informatica Inc (NYSE:INFA) with an Outperform rating. The price target for Informatica is set to $40.00. For the third quarter, Informatica had an EPS of $0.23, compared to year-ago quarter EPS of $0.16.

    William Blair initiated coverage on Lindblad Expeditions Holdings Inc (NASDAQ:LIND) with a Market Perform rating. In the third quarter, Lindblad Expeditions showed an EPS of $0.50, compared to $0.56 from the year-ago quarter. The stock has a 52-week-high of $21.91 and a 52-week-low of $11.31. At the end of the last trading period, Lindblad Expeditions closed at $16.35.

    Susquehanna initiated coverage on Forward Air Corp (NASDAQ:FWRD) with a Positive rating. The price target for Forward Air is set to $132.00. For the third quarter, Forward Air had an EPS of $1.14, compared to year-ago quarter EPS of $0.61. The stock has a 52-week-high of $112.55 and a 52-week-low of $70.93. At the end of the last trading period, Forward Air closed at $109.90.

    Susquehanna initiated coverage on Old Dominion Freight Line Inc (NASDAQ:ODFL) with a Neutral rating. The price target for Old Dominion Freight Line is set to $395.00. In the third quarter, Old Dominion Freight Line showed an EPS of $2.47, compared to $1.71 from the year-ago quarter. At the moment, the stock has a 52-week-high of $373.58 and a 52-week-low of $189.45. Old Dominion Freight Line closed at $356.81 at the end of the last trading period.

    Susquehanna initiated coverage on Saia Inc (NASDAQ:SAIA) with a Positive rating. The price target for Saia is set to $400.00. Saia earned $2.86 in the third quarter, compared to $1.56 in the year-ago quarter. At the moment, the stock has a 52-week-high of $365.50 and a 52-week-low of $171.16. Saia closed at $330.34 at the end of the last trading period.

    With a Positive rating, Susquehanna initiated coverage on TFI International Inc (NYSE:TFII). The price target seems to have been set at $132.00 for TFI International. At the moment, the stock has a 52-week-high of $120.50 and a 52-week-low of $50.10. TFI International closed at $109.12 at the end of the last trading period.

    With a Buy rating, Stifel initiated coverage on Janus International Group Inc (NYSE:JBI). The price target seems to have been set at $17.00 for Janus Intl Gr. For the third quarter, Janus Intl Gr had an EPS of $0.11, compared to year-ago quarter EPS of $0.35. The current stock performance of Janus Intl Gr shows a 52-week-high of $15.94 and a 52-week-low of $11.60. Moreover, at the end of the last trading period, the closing price was at $12.48.

    With a Equal-Weight rating, Morgan Stanley initiated coverage on Upstart Holdings Inc (NASDAQ:UPST). The price target seems to have been set at $200.00 for Upstart Holdings. The stock has a 52-week-high of $401.49 and a 52-week-low of $22.61. At the end of the last trading period, Upstart Holdings closed at $194.37.

    JP Morgan initiated coverage on RAPT Therapeutics Inc (NASDAQ:RAPT) with an Overweight rating. The price target for RAPT Therapeutics is set to $61.00. RAPT Therapeutics earned $0.63 in the third quarter, compared to $0.60 in the year-ago quarter. At the moment, the stock has a 52-week-high of $43.26 and a 52-week-low of $14.89. RAPT Therapeutics closed at $30.89 at the end of the last trading period.

    With an Overweight rating, JP Morgan initiated coverage on EVgo Inc (NASDAQ:EVGO). The price target seems to have been set at $20.00 for EVgo. At the moment, the stock has a 52-week-high of $19.59 and a 52-week-low of $7.17. EVgo closed at $12.17 at the end of the last trading period.

    Stifel initiated coverage on Apollo Endosurgery Inc (NASDAQ:APEN) with a Buy rating. The price target for Apollo Endosurgery is set to $12.00. In the third quarter, Apollo Endosurgery showed an EPS of $0.23, compared to $0.11 from the year-ago quarter. The stock has a 52-week-high of $10.39 and a 52-week-low of $3.23. At the end of the last trading period, Apollo Endosurgery closed at $8.59.

    With a Buy rating, DZ Bank initiated coverage on Cloudflare Inc (NYSE:NET). The price target seems to have been set at $200.00 for Cloudflare. For the third quarter, Cloudflare had an EPS of $0.00, compared to year-ago quarter EPS of $0.02. At the moment, the stock has a 52-week-high of $221.64 and a 52-week-low of $60.96. Cloudflare closed at $160.44 at the end of the last trading period.

    Needham initiated coverage on Bicycle Therapeutics PLC (NASDAQ:BCYC) with a Buy rating. The price target for Bicycle Therapeutics is set to $85.00. In the third quarter, Bicycle Therapeutics showed an EPS of $0.59, compared to $0.52 from the year-ago quarter. The stock has a 52-week-high of $62.08 and a 52-week-low of $17.95. At the end of the last trading period, Bicycle Therapeutics closed at $56.00.

    With an Overweight rating, JP Morgan initiated coverage on FuboTV Inc (NYSE:FUBO). The price target seems to have been set at $28.00 for FuboTV. For the third quarter, FuboTV had an EPS of $0.59, compared to year-ago quarter EPS of $1.65. The stock has a 52-week-high of $62.29 and a 52-week-low of $14.64. At the end of the last trading period, FuboTV closed at $19.77.

    With an Outperform rating, Oppenheimer initiated coverage on Green Plains Inc (NASDAQ:GPRE). The price target seems to have been set at $46.00 for Green Plains. Green Plains earned $1.18 in the third quarter, compared to $1.05 in the year-ago quarter. The current stock performance of Green Plains shows a 52-week-high of $44.27 and a 52-week-low of $11.91. Moreover, at the end of the last trading period, the closing price was at $38.36.

    Oppenheimer initiated coverage on Opiant Pharmaceuticals Inc (NASDAQ:OPNT) with an Outperform rating. The price target for Opiant Pharmaceuticals is set to $42.00. Opiant Pharmaceuticals earned $0.56 in the third quarter, compared to $0.15 in the year-ago quarter. The stock has a 52-week-high of $32.77 and a 52-week-low of $7.86. At the end of the last trading period, Opiant Pharmaceuticals closed at $32.20.

    Oppenheimer initiated coverage on Benson Hill Inc (NYSE:BHIL) with an Outperform rating. The price target for Benson Hill is set to $9.00. For the third quarter, Benson Hill had an EPS of $0.19, compared to year-ago quarter EPS of $0.11.

    See all analyst ratings initiations.

    Get the next $ABBV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABBV
    $ALL
    $ALSN
    $AMGN

    CompanyDatePrice TargetRatingAnalyst
    Old Dominion Freight Line Inc.
    $ODFL
    2/12/2026$220.00Hold → Buy
    Argus
    Pfizer Inc.
    $PFE
    2/12/2026$27.00Outperform → Neutral
    Daiwa Securities
    Saia Inc.
    $SAIA
    2/11/2026$425.00Positive → Neutral
    Susquehanna
    Cloudflare Inc.
    $NET
    2/11/2026$260.00Neutral → Outperform
    Robert W. Baird
    Gilead Sciences Inc.
    $GILD
    2/11/2026$140.00 → $170.00Buy
    Needham
    Saia Inc.
    $SAIA
    2/10/2026$250.00Equal-Weight → Underweight
    Morgan Stanley
    Linde plc
    $LIN
    2/10/2026$460.00Buy → Hold
    DZ Bank
    Green Plains Inc.
    $GPRE
    2/9/2026$17.00Equal-Weight → Overweight
    Stephens
    More analyst ratings

    $ABBV
    $ALL
    $ALSN
    $AMGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Old Dominion upgraded by Argus with a new price target

    Argus upgraded Old Dominion from Hold to Buy and set a new price target of $220.00

    2/12/26 9:50:56 AM ET
    $ODFL
    Trucking Freight/Courier Services
    Industrials

    Pfizer downgraded by Daiwa Securities with a new price target

    Daiwa Securities downgraded Pfizer from Outperform to Neutral and set a new price target of $27.00

    2/12/26 7:23:25 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Saia downgraded by Susquehanna with a new price target

    Susquehanna downgraded Saia from Positive to Neutral and set a new price target of $425.00

    2/11/26 7:50:53 AM ET
    $SAIA
    Trucking Freight/Courier Services
    Industrials

    $ABBV
    $ALL
    $ALSN
    $AMGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Mitsui Sumitomo Insurance Co Ltd bought $6,828,152 worth of shares (97,996 units at $69.68) (SEC Form 4)

    4 - BERKLEY W R CORP (0000011544) (Issuer)

    2/11/26 8:30:04 PM ET
    $WRB
    Property-Casualty Insurers
    Finance

    Amendment: Director Singh Shiv bought $53,268 worth of shares (68 units at $783.36), increasing direct ownership by 0.90% to 7,600 units (SEC Form 4)

    4/A - UNITED RENTALS, INC. (0001067701) (Issuer)

    2/9/26 4:43:20 PM ET
    $URI
    Diversified Commercial Services
    Consumer Discretionary

    Large owner Mitsui Sumitomo Insurance Co Ltd bought $2,835,251 worth of shares (40,000 units at $70.88) (SEC Form 4)

    4 - BERKLEY W R CORP (0000011544) (Issuer)

    2/6/26 8:46:48 PM ET
    $WRB
    Property-Casualty Insurers
    Finance

    $ABBV
    $ALL
    $ALSN
    $AMGN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Cloudflare Inc.

    SCHEDULE 13G/A - Cloudflare, Inc. (0001477333) (Subject)

    2/12/26 2:52:36 PM ET
    $NET
    Computer Software: Prepackaged Software
    Technology

    SEC Form 10-K filed by Eli Lilly and Company

    10-K - ELI LILLY & Co (0000059478) (Filer)

    2/12/26 1:58:32 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Brookfield Renewable Corporation Brookfield Renewable Corporat

    SCHEDULE 13G - Brookfield Renewable Corp (0001791863) (Subject)

    2/12/26 11:11:44 AM ET
    $BEPC
    Electric Utilities: Central
    Utilities

    $ABBV
    $ALL
    $ALSN
    $AMGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Roy Ranjith exercised 343 shares at a strike of $158.85 and covered exercise/tax liability with 103 shares, increasing direct ownership by 89% to 511 units (SEC Form 4)

    4 - YUM BRANDS INC (0001041061) (Issuer)

    2/12/26 10:32:31 AM ET
    $YUM
    Restaurants
    Consumer Discretionary

    COO and CPO Skeans Tracy L exercised 3,146 shares at a strike of $158.85 and covered exercise/tax liability with 1,241 shares, increasing direct ownership by 24% to 9,754 units (SEC Form 4)

    4 - YUM BRANDS INC (0001041061) (Issuer)

    2/12/26 10:30:40 AM ET
    $YUM
    Restaurants
    Consumer Discretionary

    Taco Bell, CEO, YUM CCO Tresvant Sean exercised 2,365 shares at a strike of $158.85 and covered exercise/tax liability with 845 shares, increasing direct ownership by 33% to 6,140 units (SEC Form 4)

    4 - YUM BRANDS INC (0001041061) (Issuer)

    2/12/26 10:26:54 AM ET
    $YUM
    Restaurants
    Consumer Discretionary

    $ABBV
    $ALL
    $ALSN
    $AMGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SPECTRUM LAUNCHES INVINCIBLE WIFI™, INTEGRATING WIFI 7 WITH 5G AND BATTERY BACKUP FOR CONSTANT CONNECTIVITY

    Key Takeaways: Invincible WiFi is the industry's first WiFi 7 service with 5G cellular and battery backup, seamlessly switching connections in the event of a power outage or network disruption.Available to both residential and business customers, Invincible WiFi keeps devices connected through the unexpected.STAMFORD, Conn., Feb. 12, 2026 /PRNewswire/ -- A storm rolls through and your power goes out, but your devices stay connected to WiFi and life keeps moving: working, learning, streaming and gaming continue because of Spectrum's Invincible WiFi™, the industry's first WiFi 7 service with integrated battery and 5G cellular backup. Announced today, Spectrum's Invincible WiFi sets a new stand

    2/12/26 11:00:00 AM ET
    $CHTR
    Cable & Other Pay Television Services
    Telecommunications

    Oldcastle APG Launches Innovative Outdoor Products and Solutions at International Builders' Show

    North America's Largest Building Products Manufacturer Supports Builders from Foundation to Finish ATLANTA, Feb. 12, 2026 /PRNewswire/ -- Oldcastle APG, a CRH Company, the leading provider of outdoor building solutions in North America, will showcase its newest product innovations and end-to-end builder partnership solutions at the 2026 NAHB International Builders' Show in Orlando, Fla., from February 17 – 19. As affordability and labor challenges persist, builders and developers face increasing pressure to deliver outdoor spaces that enhance livability in homes, communities and commercial environments while maximizing operational efficiency and long-term value.

    2/12/26 9:00:00 AM ET
    $CRH
    Building Materials
    Industrials

    EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

    The EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb), Firmonertinib (ArriVent BioPharma), and others in frontline and combination settings, rising therapy costs, and increasing testing rates that enable the identification of more patients with EGFR alterations. LAS VEGAS, Feb. 11, 2026 /PRNewswire/ -- DelveInsight's EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs, market share of individua

    2/11/26 5:31:00 PM ET
    $ABBV
    $AVBP
    $BDTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ABBV
    $ALL
    $ALSN
    $AMGN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    January 30, 2025 - FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain

    For Immediate Release: January 30, 2025 Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals reach the brain.  Journavx is the first dr

    1/30/25 5:46:14 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-6) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215973, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-8) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215974, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABBV
    $ALL
    $ALSN
    $AMGN
    Financials

    Live finance-specific insights

    View All

    UiPath Announces Fourth Quarter and Full Year Fiscal 2026 Financial Results Conference Call

    UiPath, Inc. (NYSE:PATH), a global leader in agentic automation, today announced it will report financial results for its fourth quarter and full year fiscal 2026 ended January 31, 2026 after the market closes on Wednesday, March 11, 2026. Management will host a conference call and webcast to discuss the Company's financial results at 5:00 pm ET. UiPath Fourth Quarter and Full Year Fiscal 2026 Financial Results Conference Call When: Wednesday, March 11, 2026 Time: 5:00 pm ET Conference ID: 13758276 Live Call: 1-877-407-8309 (US/Canada Toll-Free) or 1-201-689-8057 (Toll) Replay: A webcast replay of the conference call will be available on the investor relations website for one year. Webcas

    2/11/26 4:10:00 PM ET
    $PATH
    Computer Software: Prepackaged Software
    Technology

    Phillips 66 Announces Increase in Quarterly Dividend

    The board of directors of Phillips 66 (NYSE:PSX) has declared a quarterly dividend of $1.27 per share on Phillips 66 common stock, representing a $0.07 increase. The dividend is payable on March 4, 2026, to shareholders of record as of the close of business on Feb. 23, 2026. "We are increasing the dividend this quarter, reflecting our confidence in our ability to generate through-cycle cash flows," said Mark Lashier, chairman and CEO of Phillips 66. "The strength and durability of cash flows from our combined businesses support our priority to return capital to shareholders through a secure, competitive and growing dividend," Lashier said. "Since our formation in 2012, the annual divide

    2/11/26 11:30:00 AM ET
    $PSX
    Integrated oil Companies
    Energy

    Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results

    Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2025 financial results after the Nasdaq Global Market closes on Wednesday, Feb. 25, 2026. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its fourth quarter and full-year 2025 financial results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After register

    2/11/26 8:30:00 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $ALL
    $ALSN
    $AMGN
    Leadership Updates

    Live Leadership Updates

    View All

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems

    CALGARY, Alberta, Feb. 04, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that further to its press release of October 17, 2025 and an update on December 31, 2025, the Company has entered into an extension agreement with Vectus Biosystems Limited ("Vectus") to allow further time to complete the acquisition of the Renal Anti-Fibrotic Therapeutic Program from Vectus (the "Acquisition"). The term sheet entered into October 17th (the "Term Sheet") to acquire the novel new chemical

    2/4/26 6:00:00 PM ET
    $XRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs

    Experienced industry leader brings extensive expertise in leading breakthrough therapies through clinical development to marketing approval Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced the appointment of Antoinette Paone as Chief Development Officer ("CDO") and Head of Regulatory Affairs. Ms. Paone brings extensive experience leading regulatory strategy from clinical development through approval, including her work on Kalydeco and Orkambi at Vertex Pharmaceuticals (NASDAQ:VRTX). She joins Satellos from Generation Bio (NASDAQ:G

    1/29/26 7:00:00 AM ET
    $GBIO
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $ALL
    $ALSN
    $AMGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by CVR Energy Inc.

    SC 13D/A - CVR ENERGY INC (0001376139) (Subject)

    1/7/25 6:12:47 AM ET
    $CVI
    Integrated oil Companies
    Energy

    Amendment: SEC Form SC 13D/A filed by Bicycle Therapeutics plc

    SC 13D/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)

    12/17/24 6:46:27 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Green Plains Inc.

    SC 13G - Green Plains Inc. (0001309402) (Subject)

    11/20/24 1:25:23 PM ET
    $GPRE
    Major Chemicals
    Industrials